Literature DB >> 26115098

Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma.

Hideharu Bessho1,2,3, Bernice Wong1,2, Dachuan Huang1,2, Jing Tan1,2, Choon Kiat Ong1,2, Masatsugu Iwamura3, Stefan Hart4, Markus Dangl4, Markus Thomas5, Bin Tean Teh1,2,6.   

Abstract

The blockade of VEGF pathway has been clinically validated as an initial treatment for renal cell carcinoma (RCC). Angiopoietin-2 (Ang-2) has been indicated as a key regulator for angiogenesis escape. The effect of a novel bispecific antibody (A2V CrossMab) against both Ang-2 and VEGF was investigated in comparison with either factor. A2V CrossMab significantly reduced tumor volume, vessel density, and interstitial fluid pressure compared to either monotherapy of anti-VEGF or anti-Ang-2. Host-derived angiogenesis-related genes have been significantly down-regulated in A2V CrossMab group. These data demonstrate that A2V CrossMab has additive anti-tumor effect for the treatment of RCC.

Entities:  

Keywords:  Angiopoietin; Anti-angiogenic therapy; Interstitial fluid pressure; Renal cell carcinoma; VEGF

Mesh：

Substances：

Year:  2015        PMID： 26115098     DOI： 10.3109/07357907.2015.1047505

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  7 in total

1.  Differential Effects of Ang-2/VEGF-A Inhibiting Antibodies in Combination with Radio- or Chemotherapy in Glioma.

Authors:  Gergely Solecki; Matthias Osswald; Daniel Weber; Malte Glock; Miriam Ratliff; Hans-Joachim Müller; Oliver Krieter; Yvonne Kienast; Wolfgang Wick; Frank Winkler
Journal:  Cancers (Basel)       Date:  2019-03-06       Impact factor: 6.639

2.  Expression of Angiopoietin and VEGF in Cervical Cancer and its Clinical Significance.

Authors:  Qingyuan Lv; Weijuan Zhong; Xiabin Ye; Yang Lv; Haiying Liu; Guizhen Yan; Diwen Chen
Journal:  Open Life Sci       Date:  2018-12-31       Impact factor: 0.938

3.  Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy.

Authors:  Sai Li; Qi Zhang; Yupeng Hong
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 4.  Ang2-Targeted Combination Therapy for Cancer Treatment.

Authors:  Na Liu; Mengfang Liu; Shengqiao Fu; Jinglei Wang; Haowen Tang; Adamu Danbala Isah; Deyu Chen; Xu Wang
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

Review 5.  The use of CrossMAb technology for the generation of bi- and multispecific antibodies.

Authors:  Christian Klein; Wolfgang Schaefer; Jörg T Regula
Journal:  MAbs       Date:  2016-06-10       Impact factor: 5.857

6.  Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.

Authors:  Lauren C J Baker; Jessica K R Boult; Markus Thomas; Astrid Koehler; Tapan Nayak; Jean Tessier; Chia-Huey Ooi; Fabian Birzele; Anton Belousov; Magdalena Zajac; Carsten Horn; Clare LeFave; Simon P Robinson
Journal:  Br J Cancer       Date:  2016-08-16       Impact factor: 7.640

Review 7.  Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?

Authors:  Ana Luísa Coelho; Mónica Patrícia Gomes; Raquel Jorge Catarino; Christian Rolfo; Agostinho Marques Lopes; Rui Manuel Medeiros; António Manuel Araújo
Journal:  Oncotarget       Date:  2017-06-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.